BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients
First Drug to Attack the Cause of Dilated Cardiomyopathy
ZUG, Switzerland, and BERLIN, Feb. 26, 2018 /PRNewswire/ -- The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to an oral presentation that the drug's developer, Berlin Cures [http://www.berlincures.ch/], will make on March 11 at the American College of Cardiology's 2018 annual scientific session in Orlando, Florida.
The DNA aptamer-based compound, known as BC007, bound to and eliminated pathogenic autoantibodies directed against the beta-1 adrenoceptor, a receptor that regulates the heart's rate and contraction strength. Heart cells are harmed by autoantibodies that chronically bind to this receptor in a process that has been found to lead to heart cell death and organ failure in 80 percent of dilated cardiomyopathy patients.
In dilated cardiomyopathy, the heart's main pumping chamber, the left ventricle, is enlarged and weakened, decreasing the heart's ability to sufficiently pump blood. There are approximately five million people with dilated cardiomyopathy in the United States and Europe. In the United States alone, dilated cardiomyopathy causes approximately 10,000 deaths and 46,000 hospitalizations each year and is the most common reason for heart transplantation and the implantation of expensive cardiac assist devices.
Clinical researchers evaluated 68 subjects in the Phase 1 study and determined that a single dose of intravenous infusion of BC007 is able to eliminate autoantibodies targeting the beta-1 adrenoceptor completely and sustainably. BC007 was extremely well tolerated and did not provoke any clinically relevant side effects.
In an earlier study of 163 patients taking full anti-heart failure medication as they awaited heart transplantation, autoantibodies targeting the beta-1 adrenoceptor were eliminated by a complex blood washing procedure known as immunoadsorption, leading to significantly improved heart function and to a pronounced increase in the probability of survival. Five years after first undergoing immunoadsorption, patients had a 43 percent greater probability of survival than patients who did not undergo immunoadsorption. The findings were first reported in the August, 2012 edition of the European Journal of Heart Failure.
In addition to eliminating autoantibodies targeting the beta-1 adrenoceptor, BC007 neutralized other autoantibodies belonging to the same large family of cell-surface receptors known as G-protein-coupled receptors.
In fact, because BC007 has shown a high affinity and specificity for all G-protein-coupled receptor autoantibodies, Berlin Cures is developing additional aptamer drugs based on BC007's mechanism of action to eliminate other GPCR autoantibodies linked to pulmonary hypertension, glaucoma, pre-eclampsia and other diseases.
"With BC007, we've demonstrated the effectiveness of treating heart failure that's triggered by the pathogenic functional autoantibodies present in the vast majority of patients with dilated cardiomyopathy," Berlin Cures founder, chairman and president Dr. Johannes Müller said.
"By demonstrating that a single short infusion of BC007 results in sustained elimination of these autoantibodies, we have begun laying the groundwork for replacing costly and burdensome blood washing procedures and cardiac assist devices with BC007."
Berlin Cures plans to begin Phase 2 clinical testing of BC007 in the second quarter of 2018.
About Berlin Cures
Berlin Cures Holding AG, a privately-held company founded late in 2014 and based in Zug, Switzerland, is building a new generation of treatments based on a quarter of a century of research on autoimmune diseases conducted at the renowned Charité Berlin and at the Max-Delbrueck-Center in Berlin. The focus is developing treatments for diseases with autoimmune pathology in which functional autoantibodies directed against G-protein-coupled receptors of different types are present. Berlin Cures also has an office in Berlin, Germany.
The family of G-protein-receptors, with over 1000 different sub-types, constitutes the largest protein super-family with the physiological ability to sense molecules outside the cell. Berlin Cures holds the IP for a platform of aptamers that bind to and neutralize these functional autoantibodies, which play an important role in the pathophysiology of several autoimmune-diseases.
Recent studies involving heart failure, pulmonary hypertension, chronic fatigue syndrome, pre-eclampsia and a significant number other diseases have shown that these functional autoantibodies play a highly underestimated role in disease development and sustenance. Neutralizing these autoantibodies can lead to substantial improvements in treatment.
For more information, http://www.berlincures.ch [http://www.berlincures.ch/].
Berlin Cures Holding AG Raffaela Lutschg firstname.lastname@example.org [mailto:email@example.com] 0041 78 215 42 00
Russo Partners, LLC Tony Russo, Ph.D. Tony.Russo@russopartnersllc.com [mailto:Tony.Russo@russopartnersllc.com] 212.845.4251 Office
Amiad Finkelthal Amiad.Finkelthal@russopartnersllc.com [mailto:Amiad.Finkelthal@russopartnersllc.com] 646.942.5626 Office 917.217.1838 Mobile
Web site: http://www.berlincures.ch/